MX2007009466A - Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso. - Google Patents
Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso.Info
- Publication number
- MX2007009466A MX2007009466A MX2007009466A MX2007009466A MX2007009466A MX 2007009466 A MX2007009466 A MX 2007009466A MX 2007009466 A MX2007009466 A MX 2007009466A MX 2007009466 A MX2007009466 A MX 2007009466A MX 2007009466 A MX2007009466 A MX 2007009466A
- Authority
- MX
- Mexico
- Prior art keywords
- ifn
- bioactivity
- antibodies
- methods
- subtypes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La presente invencion incluye composiciones y metodos que incluyen anticuerpos que neutralizan selectivamente una bioactividad de al menos dos subtipos de la proteina del interferon alfa ("IFN(") para los subtipos subtipos A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b y WA de la proteina, pero no neutraliza al menos una bioactividad del subtipo D de la proteina de IFN(. Los ejemplos de bioactividad para la medicion incluyen la activacion del promotor de MxA o la actividad antiviral y las variantes, derivados y fragmentos del mismo. La invencion tambien incluye las celulas hospederas, hibridomas y plasmacitomas que producen anticuerpos. A causa de su selectividad y afinidad unicas, los anticuerpos de la presente invencion son utiles para detectar los subtipos de IFN( en la muestra o tejido y/o para las aplicaciones terapeuticas que incluyen, pero que no estan limitadas: al tratamiento y/o mejora de un trastorno relacionado con IFN( tal como SLE, lupus, diabetes del tipo I, psoriasis, SIDA y enfermedad del injerto contra el huesped.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65223305P | 2005-02-10 | 2005-02-10 | |
PCT/US2006/004643 WO2006086586A2 (en) | 2005-02-10 | 2006-02-09 | Anti-interferon alpha monoclonal antibodies and methods for use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007009466A true MX2007009466A (es) | 2007-12-07 |
Family
ID=36694481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007009466A MX2007009466A (es) | 2005-02-10 | 2006-02-09 | Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso. |
Country Status (14)
Country | Link |
---|---|
US (2) | US8080638B2 (es) |
EP (1) | EP1851248B1 (es) |
JP (2) | JP5837730B2 (es) |
KR (1) | KR101363120B1 (es) |
CN (1) | CN101155831B (es) |
AU (1) | AU2006213800B2 (es) |
BR (1) | BRPI0607490A2 (es) |
CA (1) | CA2597265C (es) |
IL (1) | IL184808A0 (es) |
MX (1) | MX2007009466A (es) |
NO (1) | NO343054B1 (es) |
RU (1) | RU2431638C2 (es) |
WO (1) | WO2006086586A2 (es) |
ZA (1) | ZA200706425B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006037247A1 (en) * | 2004-10-07 | 2006-04-13 | Universität Zürich | Type i interferon blocking agents for prevention and treatment of psoriasis |
US7888481B2 (en) | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
MX2007009466A (es) | 2005-02-10 | 2007-12-07 | Baylor Res Inst | Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso. |
EP2057190A4 (en) * | 2006-08-09 | 2010-07-28 | Baylor Res Inst | ANTI-INTERFERON ALPHA MONOCLONAL ANTIBODIES AND METHODS OF USE |
US20100143372A1 (en) * | 2006-12-06 | 2010-06-10 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
EP2687232A1 (en) * | 2006-12-06 | 2014-01-22 | MedImmune, LLC | Methods of treating systemic lupus erythematosus |
US8426170B2 (en) | 2007-01-25 | 2013-04-23 | Universite Libre De Bruxelles | Method for evaluating the response of an individual to a treatment with a type I interferon (IFN) |
JP5456658B2 (ja) * | 2007-03-30 | 2014-04-02 | メディミューン,エルエルシー | 抗体製剤 |
JP5411129B2 (ja) * | 2007-05-03 | 2014-02-12 | メディミューン,エルエルシー | インターフェロンα誘導性薬力学的マーカー |
EP2014681A1 (en) * | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
US8513208B2 (en) | 2008-02-28 | 2013-08-20 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
WO2009135861A2 (en) | 2008-05-07 | 2009-11-12 | Novo Nordisk A/S | Humanized antibodies against human interferon-alpha |
HUE047316T2 (hu) * | 2008-08-14 | 2020-04-28 | Genentech Inc | Eljárások szennyezés eltávolítására indigén fehérjekiszorításos ioncserés membrán kromatográfia alkalmazásával |
CN101580546B (zh) * | 2009-06-04 | 2011-09-14 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗人干扰素α抗体及其应用 |
CN102971012B (zh) | 2010-03-12 | 2016-05-04 | 伊缪诺金公司 | Cd37结合分子及其免疫缀合物 |
CN103596590A (zh) | 2011-04-01 | 2014-02-19 | 伊缪诺金公司 | Cd37结合分子及其免疫缀合物 |
AU2013204880B2 (en) * | 2011-04-26 | 2016-11-24 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
AR086074A1 (es) * | 2011-04-26 | 2013-11-13 | Genentech Inc | Composiciones y metodo para tratar enfermedades autoinmunes |
JP6466904B2 (ja) | 2013-03-15 | 2019-02-06 | ヤンセン バイオテツク,インコーポレーテツド | インターフェロンアルファ及びオメガ抗体アンタゴニスト |
CN112358548A (zh) | 2013-07-03 | 2021-02-12 | 因美诺克股份公司 | 人抗IFN-α抗体、IFN-α结合片段、多核苷酸、组合物、试剂盒及应用和制备方法 |
SG10202108116SA (en) | 2015-06-08 | 2021-08-30 | Debiopharm International S A | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
BR112018003147A2 (pt) | 2015-08-28 | 2018-09-18 | Debiopharm International S.A. | anticorpos e testes para detecção de cd37 |
SG11201807523PA (en) | 2016-03-10 | 2018-09-27 | Viela Bio Inc | Ilt7 binding molecules and methods of using the same |
JP2020510608A (ja) | 2016-11-02 | 2020-04-09 | デビオファーム インターナショナル, エス. アー. | 抗cd37イムノコンジュゲート療法を改善するための方法 |
CN107858449A (zh) * | 2017-12-05 | 2018-03-30 | 安徽九川生物科技有限公司 | 一种犬干扰素α生物学活性检测方法 |
MX2020005860A (es) | 2017-12-06 | 2020-09-09 | Avidity Biosciences Inc | Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica. |
RU2694672C1 (ru) * | 2018-04-27 | 2019-07-16 | Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) | Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против интерферона альфа (IFN-α) человека, антигенсвязывающий фрагмент (Fab) против IFN-α человека, содержащий указанные домены |
RU2748953C1 (ru) * | 2019-12-30 | 2021-06-02 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Рекомбинантный Fab-scFv на основе нейтрализующего антитела против интерферона бета-1а человека и антитела против рецептора ErbB2 человека |
RU2737466C1 (ru) * | 2019-12-30 | 2020-11-30 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Гуманизированное нейтрализующее антитело к интерферону-бета человека |
WO2021195469A1 (en) | 2020-03-27 | 2021-09-30 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3001687C2 (de) | 1980-01-18 | 1981-09-17 | Kläger, Karlheinz, 8901 Neusäß | Verstellbare Düse an einem handbetätigten Flüssigkeitszerstäuber |
US4423147A (en) * | 1980-04-11 | 1983-12-27 | Secher David S | Monoclonal antibody to interferon-α |
US4362155A (en) * | 1981-03-24 | 1982-12-07 | Skurkovich Simon V | Method and apparatus for the treatment of autoimmune and allergic diseases |
US4824432A (en) * | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
US4605394A (en) * | 1982-12-03 | 1986-08-12 | Simon V. Skurkovich | Methods for the treatment of pathological conditions by removing interferon from the organism |
DE3211263A1 (de) * | 1981-03-31 | 1983-01-27 | Otsuka Pharmaceutical Co. Ltd., Tokyo | Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung |
JPS60500864A (ja) * | 1983-02-04 | 1985-06-06 | ワドリ、テクナラジズ、インコーパレイティド | 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ |
GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
FR2560212B1 (fr) * | 1984-02-24 | 1989-12-29 | Unicet | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps |
AU2844889A (en) | 1988-01-22 | 1989-07-27 | Collagen Corporation | Method for suppressing the growth of normal and cancer cells |
US5889151A (en) * | 1989-10-20 | 1999-03-30 | Societe Leb-Tech | Purified human alpha interferon receptor |
KR0172969B1 (ko) * | 1991-04-17 | 1999-02-01 | 삐에르 까스뗄 | 인터페론 알파 및 베타에 대해 높은 친화력을 갖는 수용성 폴리펩티드 |
WO1993004699A1 (en) | 1991-08-30 | 1993-03-18 | Genentech, Inc. | Therapeutic method for iddm |
EP0625991B1 (en) * | 1992-02-10 | 1999-04-28 | Interferon Sciences, Inc. | Improved alpha interferon composition and method for its production from human peripheral blood leukocytes |
EP0563487A1 (en) * | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
US5821078A (en) * | 1992-09-03 | 1998-10-13 | Yeda Research And Development Co. Ltd. | Nucleic acid encoding interferon-α/β binding protein |
US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
US5780027A (en) * | 1995-07-14 | 1998-07-14 | Meiogen Biotechnology Corporation | Methods of treatment of down syndrome by interferon antagonists |
IL118096A0 (en) * | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
US6713609B1 (en) * | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
AU4070897A (en) | 1996-08-16 | 1998-03-06 | Kurt B. Osther | Method for treating diabetes |
US5804955A (en) * | 1996-10-30 | 1998-09-08 | Cherry Semiconductor Corporation | Low voltage current limit circuit with temperature insensitive foldback network |
US20030018174A1 (en) * | 1997-10-06 | 2003-01-23 | Genentech, Inc. | Monoclonal antibodies to IFNAR2 |
EP1115737A4 (en) | 1998-09-23 | 2004-11-24 | Cleveland Clinic Foundation | NEW GENES STIMULATED OR REPRESSED BY INTERFERON |
AUPP670698A0 (en) | 1998-10-23 | 1998-11-19 | Monash University | A method of regulation |
KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
JP5007007B2 (ja) | 1999-11-15 | 2012-08-22 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞 |
GB0001712D0 (en) * | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic peptides |
GB0001710D0 (en) | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
US6846486B1 (en) * | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
US6660523B2 (en) * | 2000-09-21 | 2003-12-09 | Schering Corporation | Dendritic cells; methods |
CN101612402A (zh) * | 2001-01-09 | 2009-12-30 | 贝勒研究院 | 干扰素拮抗剂和Flt3L拮抗剂的用途 |
US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
FR2822845B1 (fr) * | 2001-03-30 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
WO2004003211A1 (en) * | 2002-06-26 | 2004-01-08 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
US7741297B2 (en) | 2002-02-04 | 2010-06-22 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
AU2003295471B2 (en) * | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
NZ542988A (en) | 2003-04-23 | 2008-07-31 | Medarex Inc | Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies |
CA2546054C (en) | 2003-12-10 | 2014-05-13 | Medarex, Inc. | Interferon alpha antibodies and their uses |
WO2006037247A1 (en) * | 2004-10-07 | 2006-04-13 | Universität Zürich | Type i interferon blocking agents for prevention and treatment of psoriasis |
US7888481B2 (en) | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
MX2007009466A (es) | 2005-02-10 | 2007-12-07 | Baylor Res Inst | Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso. |
EP2057190A4 (en) | 2006-08-09 | 2010-07-28 | Baylor Res Inst | ANTI-INTERFERON ALPHA MONOCLONAL ANTIBODIES AND METHODS OF USE |
WO2009135861A2 (en) | 2008-05-07 | 2009-11-12 | Novo Nordisk A/S | Humanized antibodies against human interferon-alpha |
-
2006
- 2006-02-09 MX MX2007009466A patent/MX2007009466A/es active IP Right Grant
- 2006-02-09 JP JP2007555223A patent/JP5837730B2/ja active Active
- 2006-02-09 RU RU2007133608/10A patent/RU2431638C2/ru active
- 2006-02-09 WO PCT/US2006/004643 patent/WO2006086586A2/en active Search and Examination
- 2006-02-09 CN CN200680011269.3A patent/CN101155831B/zh active Active
- 2006-02-09 US US11/883,961 patent/US8080638B2/en active Active
- 2006-02-09 AU AU2006213800A patent/AU2006213800B2/en active Active
- 2006-02-09 CA CA2597265A patent/CA2597265C/en active Active
- 2006-02-09 BR BRPI0607490-1A patent/BRPI0607490A2/pt not_active Application Discontinuation
- 2006-02-09 EP EP06734693.2A patent/EP1851248B1/en active Active
- 2006-02-09 KR KR1020077020583A patent/KR101363120B1/ko active IP Right Grant
-
2007
- 2007-07-24 IL IL184808A patent/IL184808A0/en active IP Right Grant
- 2007-08-01 ZA ZA2007/06425A patent/ZA200706425B/en unknown
- 2007-09-06 NO NO20074512A patent/NO343054B1/no unknown
-
2011
- 2011-10-04 US US13/252,335 patent/US8333965B2/en active Active
-
2014
- 2014-02-17 JP JP2014027929A patent/JP2014111644A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL184808A0 (en) | 2007-12-03 |
JP2008529529A (ja) | 2008-08-07 |
EP1851248A2 (en) | 2007-11-07 |
JP5837730B2 (ja) | 2015-12-24 |
RU2431638C2 (ru) | 2011-10-20 |
EP1851248B1 (en) | 2016-08-10 |
AU2006213800A1 (en) | 2006-08-17 |
AU2006213800B2 (en) | 2012-02-09 |
KR20070107753A (ko) | 2007-11-07 |
US8080638B2 (en) | 2011-12-20 |
CA2597265C (en) | 2015-03-24 |
US8333965B2 (en) | 2012-12-18 |
WO2006086586A3 (en) | 2006-10-12 |
RU2007133608A (ru) | 2009-03-20 |
JP2014111644A (ja) | 2014-06-19 |
ZA200706425B (en) | 2014-07-30 |
NO20074512L (no) | 2007-10-31 |
KR101363120B1 (ko) | 2014-02-13 |
CA2597265A1 (en) | 2006-08-17 |
US20120020963A1 (en) | 2012-01-26 |
CN101155831A (zh) | 2008-04-02 |
NO343054B1 (no) | 2018-10-22 |
CN101155831B (zh) | 2015-08-19 |
WO2006086586A2 (en) | 2006-08-17 |
US20080160030A1 (en) | 2008-07-03 |
BRPI0607490A2 (pt) | 2009-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007009466A (es) | Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso. | |
WO2008021976A3 (en) | Anti-interferon alpha monoclonal antibodies and methods for use | |
Bie et al. | IL-17B: A new area of study in the IL-17 family | |
WO2005059106A3 (en) | Interferon alpha antibodies and their uses | |
Proost et al. | Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation | |
De Souza et al. | SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities | |
US20180334489A1 (en) | Targeting of cytokine antagonists | |
Doucet et al. | Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. | |
Mazzei et al. | Purification and characterization of a 26‐kDa competitive inhibitor of interleukin 1 | |
Nguyen et al. | A 16-residue peptide fragment of macrophage migration inhibitory factor, MIF-(50–65), exhibits redox activity and has MIF-like biological functions | |
DK1765860T3 (da) | Ny-ESO-T.cellereceptor med höj affinitet | |
DE602005010246D1 (de) | Oligopeptide zur verringerung erhöhter blutharnstoffkonzentration | |
RU2014122609A (ru) | Модифицированная константная область антитела | |
DK2343320T3 (da) | Anti-gitr-antistoffer og anvendelser deraf | |
ZA200508390B (en) | Compositions and methods for the therapy of inflammatory bowel disease | |
WO2006002177A3 (en) | Interferon alpha receptor 1 antibodies and their uses | |
WO2008060813A3 (en) | High affinity antibody antagonists of interleukin-13 receptor alpha 1 | |
DK1761553T3 (da) | MHC molecule-binding tumor-associated peptides | |
SG163548A1 (en) | Methods and compositions with enhanced therapeutic activity | |
BR0008688A (pt) | Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18 | |
IL207146A0 (en) | Antibodies capable of competing with anti-il-22ra monoclonal antibodies | |
ATE520025T1 (de) | Test für morbus-parkinson-therapeutika | |
NO20030495L (no) | Peptider som presenteres av celler | |
WO2004080957A3 (en) | Use of adnf polypeptides for treating anxiety and depression | |
Chew et al. | Potential combinatorial effects of recombinant atypical chemokine receptors in breast cancer cell invasion: a research perspective |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |